Edition:
India

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

24.85EUR
18 Jun 2019
Change (% chg)

€0.55 (+2.26%)
Prev Close
€24.30
Open
€24.14
Day's High
€24.91
Day's Low
€24.14
Volume
513,896
Avg. Vol
644,875
52-wk High
€27.12
52-wk Low
€21.57

Latest Key Developments (Source: Significant Developments)

Grifols To Pay Dividend, Reaffirms 1.40 Bln Euros In Capital Investments
Friday, 24 May 2019 

May 24 (Reuters) - Grifols SA ::SAYS TO PAY NET DIVIDEND OF 0.008 EUROS/CLASS B SHARE ON JUNE 11.TO PAY ORDINARY NET DIVIDEND OF 0.118 EUROS PER SHARE ON JUNE 11.REAFFIRMS ITS LONG-TERM SUSTAINABLE GROWTH STRATEGY WITH 1.40 BILLION EUROS IN CAPITAL INVESTMENTS IN 2018-2022.  Full Article

Grifols Q1 Net Profit Down At 114.4 Mln Euros YoY
Tuesday, 7 May 2019 

May 7 (Reuters) - Grifols SA ::Q1 NET PROFIT 114.4 MILLION EUROS VERSUS 143.4 MILLION EUROS YEAR AGO.Q1 EBITDA 305.6 MILLION EUROS VERSUS 297.4 MILLION EUROS YEAR AGO.Q1 NET SALES 1.16 BILLION EUROS VERSUS 1.02 BILLION EUROS YEAR AGO.Q1 RESEARCH AND DEVELOPMENT NET INVESTMENT 89.3 MILLION EUROS VERSUS 73.5 MILLION EUROS YEAR AGO.Q1 ADJUSTED NET PROFIT 148.2 MILLION EUROS VERSUS 160.8 MILLION EUROS YEAR AGO.  Full Article

Grifols Exercises Call Option Over 51 Pct Of IBBI For USD 100 Mln
Thursday, 2 May 2019 

May 2 (Reuters) - Grifols SA ::EXERCISES CALL OPTION OVER 51 PERCENT OF INTERSTATE BLOOD BANK, INC. (IBBI).SAYS PURCHASE PRICE OF USD 100 MILLION.ON APRIL 8, 2016 GRIFOLS ACQUIRED 49 PERCENT OF IBBI .  Full Article

Rigel Pharmaceuticals Enters Collaboration And License Agreement With Grifols S.A. To Commercialize Fostamatinib In Europe
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Grifols SA ::RIGEL PHARMACEUTICALS ENTERS COLLABORATION AND LICENSE AGREEMENT WITH GRIFOLS, S.A. TO COMMERCIALIZE FOSTAMATINIB IN EUROPE.RIGEL PHARMACEUTICALS - TO RECEIVE AN UPFRONT PAYMENT OF $30 MILLION, WITH POTENTIAL FOR $297.5 MILLION IN TOTAL REGULATORY AND COMMERCIAL MILESTONES.RIGEL PHARMACEUTICALS INC - GRIFOLS GAINS EXCLUSIVE RIGHTS TO FOSTAMATINIB IN ALL POTENTIAL INDICATIONS IN EUROPE AND TURKEY.RIGEL PHARMACEUTICALS INC - TO RECEIVE STEPPED ROYALTY PAYMENTS REACHING 30% OF NET SALES OF FOSTAMATINIB.RIGEL PHARMACEUTICALS - ANTICIPATES A DECISION FROM EMA'S COMMITTEE ON HUMAN MEDICINAL PRODUCTS BY Q4 OF 2019 AND POTENTIAL EUROPEAN APPROVAL BY 2019 END.  Full Article

Grifols Receives FDA Approval Of Erytra Eflexis
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Grifols SA ::GRIFOLS RECEIVES FDA APPROVAL OF ERYTRA EFLEXIS®, THE LATEST ADVANCEMENT IN SCALABLE BLOOD TYPING SOLUTIONS.  Full Article

Grifols Sells Biotest And Haema To Scranton For $537 Mln
Monday, 31 Dec 2018 

Dec 31 (Reuters) - Grifols SA ::SAYS SELLS BIOTEST US CORPORATION AND HAEMA AG TO SCRANTON ENTERPRISES BV FOR $537 MILLION.WILL HAVE CALL OPTION OVER ALL SHARES OF COMPANIES SOLD TO SCRANTON.  Full Article

Medcom Tech Says Grifols To Invest In Its Diagnostic Unit MedcomAdvance
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Medcom Tech SA ::SAYS ITS UNIT MEDCOMADVANCE SIGNS AGREEMENT WITH GRIFOLS TO TAKE FORWARD ITS CLINICAL DIAGNOSIS TECHNOLOGY.GRIFOLS TO ENTER SHAREHOLDING OF 51 PERCENT IN MEDCOMADVANCE WITH INVESTMENT OF 10 MILLION EUROS.  Full Article

Grifols 9-Month Net Profit Up 8.5 Pct YoY
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Grifols SA ::9-MONTH NET PROFIT 468.3 MILLION EUROS VERSUS 431.8 MILLION EUROS YEAR AGO.9-MONTH EBITDA 939.4 MILLION EUROS VERSUS 960.9 MILLION EUROS YEAR AGO.9-MONTH NET REVENUE 3.26 BILLION EUROS VERSUS 3.25 BILLION EUROS YEAR AGO.9-MONTH RESEARCH AND DEVELOPMENT NET INVESTMENT 209.9 MILLION EUROS VERSUS 201.6 MILLION EUROS YEAR AGO.  Full Article

Grifols Obtains 85 Mln Euro Loan From EIB
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Grifols SA ::SAYS OBTAINED NEW LONG-TERM LOAN WITH EUROPEAN INVESTMENT BANK (EIB) TOTALING 85 MILLION EUROS.SAYS CONDITIONS INCLUDE FIXED INTEREST RATE OVER 10 YEARS AND TWO-YEAR GRACE PERIOD.  Full Article

Grifols Receives FDA Approval For New Manufacturing Facility For Production Of Recombinant Proteins
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Grifols SA ::GRIFOLS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE NEW CONSOLIDATED MANUFACTURING FACILITY (CMF) FOR PRODUCTION OF RECOMBINANT PROTEINS.  Full Article

Photo

Spain's Grifols, China's Shanghai RAAS form strategic alliance

Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China.